At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.
H. Miles Prince, MD, MBBS
Advertisement
H. Miles Prince, MD, MBBS, is an adjunct professor in the School of translational medicine at Monash University, professor and director of Cancer Immunology and Molecular Oncology at Epworth Healthcare, and a hematologist at the Peter MacCallum Cancer Center.
Articles by H. Miles Prince, MD, MBBS
H. Miles Prince, MD, MBBS discusses data for mogamulizumab from MAVORIC vs real-world vorinostat in R/R MF and SS.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
The OncFive: Top Oncology Articles for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5